VIA
TERN

Virtus Investment Advisers’s Terns Pharmaceuticals TERN Stock Holding History

Virtus Investment Advisers’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$319K Buy
6,058
+146
+2% +$6K 0.09% 268
2025
Q4 		$239K Sell
5,912
-23,041
-80% -$532K 0.06% 348
2025
Q3 		$217K Buy
28,953
+5,026
+21% +$32.1K 0.06% 254
2025
Q2 		$89.2K Sell
23,927
-986
-4% -$3.08K 0.03% 385
2025
Q1 		$68.8K Buy
+24,913
New +$102K 0.02% 458

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Virtus Investment Advisers's TERN Position: Q1 2026 in Review

Virtus Investment Advisers increased its Terns Pharmaceuticals (TERN) stake by 2.5% in Q1 2026, buying an estimated $6K and bringing the position to 6,058 shares worth $319K. The position accounts for 0.09% of the portfolio, ranked #268.

Virtus Investment Advisers first reported a position in TERN in Q1 2025 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Virtus Investment Advisers held 6,058 shares of Terns Pharmaceuticals worth $319K as of Q1 2026.
  • Virtus Investment Advisers bought 146 Terns Pharmaceuticals shares in Q1 2026, an estimated $6K.
  • Terns Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q1 2026, its #268 holding.
  • Virtus Investment Advisers first reported a position in Terns Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.